Caribou Biosciences, Inc. (CRBU) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 60 transactions totaling $963.5K, demonstrating a bearish sentiment with -$364.9K in net insider flow. The most recent transaction on Feb 24, 2026 involved a sale of 1,066 shares valued at $2.1K.
No significant insider buying has been recorded for CRBU in the recent period.
No significant insider selling has been recorded for CRBU in the recent period.
Based on recent SEC filings, insider sentiment for CRBU is bearish with an Insider Alignment Score of 31/100 and a net flow of -$364.9K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Caribou Biosciences, Inc. (CRBU) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading CRBU stock, having executed 60 transactions in the past 90 days. The most active insider is Steven Kanner (Executive), who has made 12 transactions totaling $1.1M.
Get notified when executives and directors at CRBU file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | M. Albertson Tina | Chief Medical Officer | Sale | 1,066 | $1.96 | $2.1K | |
| Feb 24, 2026 | Ahmad Khan Ruhi | Chief Business Officer | Sale | 6,938 | $1.96 | $13.6K | |
| Feb 24, 2026 | G. Mcclung Barbara | Chief Legal Officer | Sale | 6,938 | $1.96 | $13.6K | |
| Feb 24, 2026 | P. Kelly Timothy | Chief Technology Officer | Sale | 3,147 | $1.96 | $6.2K | C-Suite |
| Feb 20, 2026 | M. Albertson Tina | Chief Medical Officer | Award | 247,500 | $N/A | $0 | |
| Feb 20, 2026 | M. Albertson Tina | Chief Medical Officer | Award | 55,000 | $N/A | $0 | |
| Feb 20, 2026 | Ahmad Khan Ruhi | Chief Business Officer | Award | 202,500 | $N/A | $0 | |
| Feb 20, 2026 | Ahmad Khan Ruhi | Chief Business Officer | Award | 45,000 | $N/A | $0 | |
| Feb 20, 2026 | G. Mcclung Barbara | Chief Legal Officer | Award | 202,500 | $N/A | $0 | |
| Feb 20, 2026 | G. Mcclung Barbara | Chief Legal Officer | Award | 45,000 | $N/A | $0 | |
| Feb 20, 2026 | P. Kelly Timothy | Chief Technology Officer | Award | 202,500 | $N/A | $0 | C-Suite |
| Feb 20, 2026 | P. Kelly Timothy | Chief Technology Officer | Award | 45,000 | $N/A | $0 | C-Suite |
| Feb 20, 2024 | Kanner Steven | Executive | Award | 33,000 | $N/A | $0 | |
| Feb 20, 2024 | E. Haurwitz Rachel | Executive | Award | 118,700 | $N/A | $0 | |
| Feb 20, 2024 | Ahmad Khan Ruhi | Executive | Award | 33,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Exercise(M) | 21 | $784.3K | 44.9% |
Sale(S) | 7 | $664.2K | 38.0% |
Purchase(P) | 11 | $299.3K | 17.1% |
Award(A) | 15 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Conversion(C) | 4 | $0 | 0.0% |
Insider selling pressure at Caribou Biosciences, Inc. has increased, with 10 insiders executing 60 transactions across all time. Total sales of $664.2K significantly outpace purchases of $299.3K, resulting in a net outflow of $364.9K. This selling activity appears largely discretionary, which may warrant closer attention from investors.